108 related articles for article (PubMed ID: 17523713)
1. What Is the Best Strategy for Converting from Twice-Daily Divalproex to a Once-Daily Divalproex ER Regimen? : Examinations and Answers via Computer Simulations.
Reed RC; Dutta S
Clin Drug Investig; 2004; 24(9):509-21. PubMed ID: 17523713
[TBL] [Abstract][Full Text] [Related]
2. Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: evidence via computer simulations and implications for epilepsy therapy.
Reed RC; Dutta S; Liu W
Epilepsy Res; 2009 Dec; 87(2-3):260-7. PubMed ID: 19892524
[TBL] [Abstract][Full Text] [Related]
3. Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations.
Reed RC; Dutta S; Cavanaugh JH; Locke C; Granneman GR
Epilepsy Behav; 2006 Mar; 8(2):391-6. PubMed ID: 16473558
[TBL] [Abstract][Full Text] [Related]
4. Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug : as shown by once-daily divalproex-ER.
Dutta S; Reed RC
Clin Drug Investig; 2006; 26(12):681-90. PubMed ID: 17274675
[TBL] [Abstract][Full Text] [Related]
5. Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician.
Dutta S; Reed RC
J Clin Pharm Ther; 2006 Aug; 31(4):321-9. PubMed ID: 16882100
[TBL] [Abstract][Full Text] [Related]
6. Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER?
Reed RC; Dutta S
Ther Drug Monit; 2006 Jun; 28(3):413-8. PubMed ID: 16778728
[TBL] [Abstract][Full Text] [Related]
7. Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications.
Dutta S; Reed RC; O'Dea RF
Ann Pharmacother; 2006 Apr; 40(4):619-25. PubMed ID: 16569797
[TBL] [Abstract][Full Text] [Related]
8. Divalproex to divalproex extended release conversion.
Dutta S; Reed RC
Clin Drug Investig; 2004; 24(9):495-508. PubMed ID: 17523712
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability of a Divalproex Extended-Release Formulation versus the Conventional Divalproex Formulation in Adult Patients Receiving Enzyme-Inducing Antiepileptic Drugs.
Sommerville KW; Dutta S; Biton V; Zhang Y; Cloyd JC; Uthman B
Clin Drug Investig; 2003; 23(10):661-70. PubMed ID: 17535081
[TBL] [Abstract][Full Text] [Related]
10. Drug-Drug Interaction Studies of Paliperidone and Divalproex Sodium Extended-Release Tablets in Healthy Participants and Patients with Psychiatric Disorders.
Remmerie B; Ariyawansa J; De Meulder M; Coppola D; Berwaerts J
J Clin Pharmacol; 2016 Jun; 56(6):683-92. PubMed ID: 26412032
[TBL] [Abstract][Full Text] [Related]
11. Bioavailability of divalproex extended-release formulation relative to the divalproex delayed-release formulation.
Dutta S; Zhang Y
Biopharm Drug Dispos; 2004 Nov; 25(8):345-52. PubMed ID: 15378557
[TBL] [Abstract][Full Text] [Related]
12. A pharmacokinetic and clinical evaluation of switching patients with bipolar I disorder from delayed-release to extended-release divalproex.
Davis LL; Li X; Bartolucci AA; Williford RB; Lowe JS
J Clin Psychiatry; 2007 Oct; 68(10):1546-51. PubMed ID: 17960970
[TBL] [Abstract][Full Text] [Related]
13. Oral/intravenous maintenance dosing of valproate following intravenous loading: a simulation.
Dutta S; Cloyd JC; Granneman GR; Collins SD
Epilepsy Res; 2003 Feb; 53(1-2):29-38. PubMed ID: 12576165
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, Safety, and Retention Rate of Extended-Release Divalproex Versus Conventional Delayed-Release Divalproex: A Meta-Analysis of Controlled Clinical Trials.
Zhang CQ; Li HY; Wan Y; Bai XY; Gan L; Wang J; Sun HB
Front Pharmacol; 2022; 13():811017. PubMed ID: 35479307
[No Abstract] [Full Text] [Related]
15. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States.
Dutta S; Reed RC
Epilepsy Res; 2007 Mar; 73(3):275-83. PubMed ID: 17208410
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety, and retention rate of extended-release divalproex versus conventional delayed-release divalproex: A protocol for systematic review and meta-analysis.
Zhang CQ; Bai XY; Wan Y; Li HY; Sun H
Medicine (Baltimore); 2021 Dec; 100(50):e28290. PubMed ID: 34918705
[TBL] [Abstract][Full Text] [Related]
17. Conversion from delayed-release sodium valproate to extended-release sodium valproate: initial results and long-term follow-up.
McCabe PH; Michel NC; McNew CD; Lehman EB
Epilepsy Behav; 2006 May; 8(3):601-5. PubMed ID: 16678766
[TBL] [Abstract][Full Text] [Related]
18. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers.
Dutta S; Reed RC; Cavanaugh JH
J Clin Pharmacol; 2004 Jul; 44(7):737-42. PubMed ID: 15199078
[TBL] [Abstract][Full Text] [Related]
19. The use of Monte Carlo simulations to study the effect of poor compliance on the steady state concentrations of valproic acid following administration of enteric-coated and extended release divalproex sodium formulations.
Ahmad AM; Douglas Boudinot F; Barr WH; Reed RC; Garnett WR
Biopharm Drug Dispos; 2005 Dec; 26(9):417-25. PubMed ID: 16216031
[TBL] [Abstract][Full Text] [Related]
20. Successful initiation of combined therapy with valproate sodium injection and divalproex sodium extended-release tablets in the epilepsy monitoring unit.
Boggs JG; Preis K
Epilepsia; 2005 Jun; 46(6):949-51. PubMed ID: 15946337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
